HF
AVTX icon

HRT Financial’s Avalo Therapeutics AVTX Stock Holding History

HRT Financial’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-48,105
Closed -$718K – 4173
2026
Q1 		$718K Buy
+48,105
New +$752K ﹤0.01% 2267
2025
Q2 		– Sell
-10,289
Closed -$82K – 2592
2025
Q1 		$82K Sell
10,289
-29,711
-74% -$225K ﹤0.01% 2178
2024
Q4 		$297K Buy
+40,000
New +$428K ﹤0.01% 1722
2023
Q3 		– Sell
-55
Closed -$4K – 2388
2023
Q2 		$4K Buy
+55
New +$37K ﹤0.01% 2240
2021
Q4 		– Sell
-34
Closed -$210K – 3170
2021
Q3 		$210K Buy
+34
New +$276K ﹤0.01% 2653

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

HRT Financial's AVTX Position: Q2 2026 in Review

HRT Financial sold out of Avalo Therapeutics (AVTX) in Q2 2026, closing a stake of 48,105 shares — an estimated $718K sold.

HRT Financial first reported a position in AVTX in Q3 2021 and held it in 5 quarters. The position peaked at $718K in Q1 2026. 125 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • HRT Financial reported no remaining Avalo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • HRT Financial sold 48,105 Avalo Therapeutics shares in Q2 2026, an estimated $718K.
  • HRT Financial first reported a position in Avalo Therapeutics in Q3 2021 and held it in 5 quarters.
  • HRT Financial's Avalo Therapeutics position peaked at $718K in Q1 2026.
  • 125 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on HRT Financial's 13F filing for Q2 2026, filed 14 Aug 2026.